Bayer Granted Payment Code For Serum HER-2 Test; Herceptin Labeling Next?
This article was originally published in The Gray Sheet
Executive Summary
A unique CPT code for Bayer Diagnostics' serum HER-2/neu oncoprotein test (83950) will be effective January 2002. The Centers for Medicare & Medicaid Services is proposing the test be reimbursed at $89.01
You may also be interested in...
Abbott/Vysis’ PathVysion HER-2 Assay Endorsed By Herceptin Panel Review
Genentech's Herceptin package insert to include use of Vysis' PathVysion fluorescence in situ hybridization (FISH) test should address potential discrepancies in assay results compared with immunohistochemistry (IHC) tests, FDA's Oncologic Drugs Advisory Committee concluded
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.